An Investigation into the Prevalence of Migraine and Its
Prophylactic Treatment Patterns in the Czech Republic: An
Observational Study

J 2020

An Investigation into the Prevalence of Migraine and Its Prophylactic Treatment Patterns in the Czech Republic: An Observational Study

DOLEZIL, David, Jolana MARKOVA, Jiri KLIMES, Zuzana POCIKOVA, Filip DOSTAL et. al.

Basic information

Original name

An Investigation into the Prevalence of Migraine and Its Prophylactic Treatment Patterns in the Czech Republic: An Observational Study

Authors

DOLEZIL, David (203 Czech Republic), Jolana MARKOVA (203 Czech Republic), Jiri KLIMES (203 Czech Republic, guarantor), Zuzana POCIKOVA (203 Czech Republic), Filip DOSTAL (203 Czech Republic), Radka ŠTĚPÁNOVÁ (203 Czech Republic, belonging to the institution) and Adam SVOBODNIK (203 Czech Republic)

Edition

JOURNAL OF PAIN RESEARCH, ALBANY, DOVE MEDICAL PRESS LTD, 2020, 1178-7090

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30210 Clinical neurology

Country of publisher

New Zealand

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.133

RIV identification code

RIV/00216224:14110/20:00117300

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.2147/JPR.S273119

UT WoS

000591357300001

Keywords in English

CGRP; prophylactics; triptans; claims database

Abstract

V originále

Purpose: A national primary and secondary healthcare-level study in the Czech Republic has not yet been conducted to evaluate the prevalence of migraine. We analyzed the current treatment patterns (acute and prophylactic) in migraine patients and the number of migraine patients potentially eligible for treatment with recent calcitonin gene-related peptide (CGRP) pathway-targeted therapies. Methods: This retrospective study utilized the Ministry of the Interior Health Insurance Fund claims database of the Czech Republic wherein every citizen is insured. Migraine patients with or without aura, and potentially on triptan therapy were included in this study (index years 2012-2016). The prevalence approach included all patients (new and old) present in each index year. Prophylactic therapies were followed fOor three and seven years prior to the index year, including the index year, until 2010. The incidence approach included all patients first diagnosed in each index year. Prophylactic therapies were followed for the next three years, including the index year, until 2017 following incidence approach. The primary endpoint of this study was to determine the rate of migraine prevalence and diagnosis for each index year during the period 2012-2016. The study also evaluated prophylactic and acute treatment patterns and comorbidities among patients in 2016. Results: The rate of migraine prevalence was 1% and the rate of diagnosis was 0.2-0.4%. By prevalence approach, approximately 39% of the patients were on prophylactics, and 11.2% and 21.6% of the patient population had two prior treatment failures (three- and seven-year recall period, respectively). Antiepileptics (26%) and beta blockers (15.8%) were the most prescribed prophylactics, and sumatriptan was the predominant triptan used (12%) for acute treatment. Conclusion: Taking into account the number of inhabitants in the Czech Republic (10.7 million), there could be up to 23,000 adult patients eligible for novel CGRP therapies.

Citovat

DOLEZIL, David, Jolana MARKOVA, Jiri KLIMES, Zuzana POCIKOVA, Filip DOSTAL, Radka ŠTĚPÁNOVÁ and Adam SVOBODNIK. An Investigation into the Prevalence of Migraine and Its Prophylactic Treatment Patterns in the Czech Republic: An Observational Study. JOURNAL OF PAIN RESEARCH. ALBANY: DOVE MEDICAL PRESS LTD, 2020, vol. 13, No 2020, p. 2895-2906. ISSN 1178-7090. Available from: https://dx.doi.org/10.2147/JPR.S273119.

@article{1706836,
   author = {Dolezil, David and Markova, Jolana and Klimes, Jiri and Pocikova, Zuzana and Dostal, Filip and Štěpánová, Radka and Svobodnik, Adam},
   article_location = {ALBANY},
   article_number = {2020},
   doi = {http://dx.doi.org/10.2147/JPR.S273119},
   keywords = {CGRP; prophylactics; triptans; claims database},
   language = {eng},
   issn = {1178-7090},
   journal = {JOURNAL OF PAIN RESEARCH},
   title = {An Investigation into the Prevalence of Migraine and Its Prophylactic Treatment Patterns in the Czech Republic: An Observational Study},
   url = {https://www.dovepress.com/front_end/cr_data/cache/pdf/download_1607587410_5fd1d652e7375/jpr-273119-an-investigation-into-the-prevalence-of-migraine-and-its-pro.pdf},
   volume = {13},
   year = {2020}
}

TY  - JOUR
ID  - 1706836
AU  - Dolezil, David - Markova, Jolana - Klimes, Jiri - Pocikova, Zuzana - Dostal, Filip - Štěpánová, Radka - Svobodnik, Adam
PY  - 2020
TI  - An Investigation into the Prevalence of Migraine and Its Prophylactic Treatment Patterns in the Czech Republic: An Observational Study
JF  - JOURNAL OF PAIN RESEARCH
VL  - 13
IS  - 2020
SP  - 2895-2906
EP  - 2895-2906
PB  - DOVE MEDICAL PRESS LTD
SN  - 11787090
KW  - CGRP
KW  - prophylactics
KW  - triptans
KW  - claims database
UR  - https://www.dovepress.com/front_end/cr_data/cache/pdf/download_1607587410_5fd1d652e7375/jpr-273119-an-investigation-into-the-prevalence-of-migraine-and-its-pro.pdf
L2  - https://www.dovepress.com/front_end/cr_data/cache/pdf/download_1607587410_5fd1d652e7375/jpr-273119-an-investigation-into-the-prevalence-of-migraine-and-its-pro.pdf
N2  - Purpose: A national primary and secondary healthcare-level study in the Czech Republic has not yet been conducted to evaluate the prevalence of migraine. We analyzed the current treatment patterns (acute and prophylactic) in migraine patients and the number of migraine patients potentially eligible for treatment with recent calcitonin gene-related peptide (CGRP) pathway-targeted therapies. Methods: This retrospective study utilized the Ministry of the Interior Health Insurance Fund claims database of the Czech Republic wherein every citizen is insured. Migraine patients with or without aura, and potentially on triptan therapy were included in this study (index years 2012-2016). The prevalence approach included all patients (new and old) present in each index year. Prophylactic therapies were followed fOor three and seven years prior to the index year, including the index year, until 2010. The incidence approach included all patients first diagnosed in each index year. Prophylactic therapies were followed for the next three years, including the index year, until 2017 following incidence approach. The primary endpoint of this study was to determine the rate of migraine prevalence and diagnosis for each index year during the period 2012-2016. The study also evaluated prophylactic and acute treatment patterns and comorbidities among patients in 2016. Results: The rate of migraine prevalence was 1% and the rate of diagnosis was 0.2-0.4%. By prevalence approach, approximately 39% of the patients were on prophylactics, and 11.2% and 21.6% of the patient population had two prior treatment failures (three- and seven-year recall period, respectively). Antiepileptics (26%) and beta blockers (15.8%) were the most prescribed prophylactics, and sumatriptan was the predominant triptan used (12%) for acute treatment. Conclusion: Taking into account the number of inhabitants in the Czech Republic (10.7 million), there could be up to 23,000 adult patients eligible for novel CGRP therapies.
ER  -

DOLEZIL, David, Jolana MARKOVA, Jiri KLIMES, Zuzana POCIKOVA, Filip DOSTAL, Radka ŠTĚPÁNOVÁ and Adam SVOBODNIK. An Investigation into the Prevalence of Migraine and Its Prophylactic Treatment Patterns in the Czech Republic: An Observational Study. \textit{JOURNAL OF PAIN RESEARCH}. ALBANY: DOVE MEDICAL PRESS LTD, 2020, vol.~13, No~2020, p.~2895-2906. ISSN~1178-7090. Available from: https://dx.doi.org/10.2147/JPR.S273119.

Detailed Information on Publication Record